This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Diabetes, obesity & metabolism, 28(2), 1490-1498
Citation
Wharton, Sean; le Roux, Carel W; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brueckmann, Martina; Startseva, Elena; Kloer, Isabel M; Kaplan, Lee M. (2026). Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.. Diabetes, obesity & metabolism, 28(2), 1490-1498. https://doi.org/10.1111/dom.70263